Clinical Trials Logo

Preleukemia clinical trials

View clinical trials related to Preleukemia.

Filter by:

NCT ID: NCT05457010 Recruiting - Clinical trials for Acute Myeloid Leukemia

Phase I Study of Cell Therapies for the Treatment of Patients With Relapsed or Refractory AML or High-risk MDS

Start date: November 28, 2022
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the safety and preliminary activity of ARC-T cells and SPRX002 in participants with relapsed or refractory acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS)

NCT ID: NCT05455294 Recruiting - Clinical trials for Acute Myeloid Leukemia

Combination Navitoclax, Venetoclax and Decitabine for Advanced Myeloid Neoplasms

Start date: July 18, 2022
Phase: Phase 1
Study type: Interventional

The purpose of this research study is to test the safety of a new three drug combination of navitoclax, decitabine, and venetoclax to treat advanced myeloid malignancies. The names of the drugs involved in this study are: - Venetoclax - Decitabine - Navitoclax

NCT ID: NCT05448599 Recruiting - Clinical trials for Acute Myeloid Leukemia

A Clinical Study of 6MW3211 Monotherapy or Combination Therapy for AML or MDS

Start date: July 8, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

This study is aimed to evaluate the efficacy, safety, immunogenicity and pharmkinetics, pharmacodynamics of 6MW3211 as monotherapy and in combination with AZA or AZA plus VEN in patients with AML/MDS.

NCT ID: NCT05428969 Recruiting - Clinical trials for Acute Myeloid Leukemia

A Study to Assess Safety, Tolerability and Preliminary Efficacy of Bexmarilimab in Combination With Standard of Care in Patients With Hematological Malignancies (BEXMAB)

Start date: June 2, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

This is a study to assess the safety of increasing dose levels of bexmarilimab when combined with standard of care (SoC) in patients with myelodysplastic syndrome (MDS) or chronic myelomonocytic leukemia (CMML) or acute myeloid leukemia (AML); Phase 1 aims to identify the recommended phase 2 dose (RP2D) of bexmarilimab based on safety, tolerability and pharmacological activity; Phase 2 will investigate the preliminary efficacy of the combination treatment in selected indications from Phase 1.

NCT ID: NCT05426798 Recruiting - Clinical trials for Recurrent/Refractory Acute Myeloid Leukemia, Myelodysplastic Syndromes

Clinical Study of TQB2618 Injection in Combination With Demethylation Drugs in Patients With Recurrent/Refractory Acute Myeloid Leukemia, Myelodysplastic Syndromes

Start date: April 29, 2022
Phase: Phase 1
Study type: Interventional

This project is an open, dose escalation and expansion phase I clinical study. The first phase is a dose escalation study, and the second phase is a dose expansion study based on the Maximum tolerated dose (MTD) / Recommended Phase II Dose (RP2D) obtained in the first phase. The purpose is to evaluate the tolerability and initially evaluate the antitumor efficacy of TQB2618 injection combined with demethylation drugs in patients with recurrent/refractory acute myeloid leukemia, myelodysplastic syndromes.

NCT ID: NCT05379166 Recruiting - Clinical trials for Secondary Myelodysplastic Syndrome

Venetoclax and Azacitidine for Treatment of Therapy Related or Secondary Myelodysplastic Syndrome

Start date: June 23, 2022
Phase: Phase 2
Study type: Interventional

This phase II trial studies the effect of venetoclax and azacitidine in treating patients with therapy related or secondary myelodysplastic syndrome. Venetoclax may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival. Chemotherapy drugs, such as azacitidine, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving venetoclax in combination with azacitidine may work better in treating patients with therapy related or secondary myelodysplastic syndrome.

NCT ID: NCT05365035 Recruiting - Clinical trials for Myelodysplastic Syndromes

A Phase II Study of Cladribine and Low Dose Cytarabine in Combination With Venetoclax, Alternating With Azacitidine and Venetoclax, in Patients With Higher-risk Myeloproliferative Chronic Myelomonocytic Leukemia or Higher-risk Myelodysplastic Syndromes With Excess Blasts

Start date: September 23, 2022
Phase: Phase 2
Study type: Interventional

To learn if the combination of cladribine, cytarabine, venetoclax, and azacitidine can help to control higher-risk myelodysplastic syndrome (MDS) with excess blasts and/or higher-risk chronic myelomonocytic leukemia (CMML).

NCT ID: NCT05342584 Recruiting - Clinical trials for Acute Myeloid Leukemia

Venetoclax Plus Intensive Chemotherapy in AML and Advanced MDS

Start date: May 25, 2022
Phase: Phase 1
Study type: Interventional

This is a Phase 1b, open-label study evaluating Venetoclax in combination with intensive induction and consolidation chemotherapy in previously untreated, adult patients with acute myeloid leukemia. In Part 1, the dose escalation phase, the safety and tolerability of the combination with Venetoclax at different doses and duration will inform the appropriate dose(s) and regimen(s) for Part 2. In Part 2, the dose expansion phase, a maximum of 28 additional patients will be randomized 1:1 to the MTD determined in Part 1 and the starting dose (assuming the MTD is not the starting dose), to further evaluate the safety and efficacy of the study drug combination.

NCT ID: NCT05308264 Recruiting - Clinical trials for Low Risk Myelodysplastic Syndromes

Study of R289 in Participants With Lower-risk Myelodysplastic Syndromes (LR MDS)

Start date: September 12, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

Phase 1b Study of R289 in Participants with Lower-risk Myelodysplastic Syndromes (LR MDS)

NCT ID: NCT05292664 Recruiting - Clinical trials for Acute Lymphoblastic Leukemia, in Relapse

Venetoclax Basket Trial for High Risk Hematologic Malignancies

Start date: March 29, 2023
Phase: Phase 1
Study type: Interventional

This trial is evaluating the safety and tolerability of venetoclax with chemotherapy in pediatric and young adult patients with hematologic malignancies, including myelodysplastic syndrome (MDS), acute myeloid leukemia derived from myelodysplastic syndrome (MDS/AML), and acute lymphoblastic leukemia (ALL)/lymphoblastic lymphoma (LBL). The names of the study drugs involved in this study are below. Please note this is a list for the study as a whole, participants will receive drugs according to disease cohort. - Venetoclax - Azacitidine - Cytarabine - Methotrexate - Hydrocortisone - Leucovorin - Dexamethasone - Vincristine - Doxorubicin - Dexrazoxane - Calaspargase pegol - Hydrocortisone